MYCOF News and Press, New Age Brands From 11/24/20

VANCOUVER, British Columbia, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (the “ Company ”) (CSE:MYCO | OTC:MYCOF) announces that its previously issued financial statements for the fiscal year ended December 31, 2019, and the three- and six-month perio...

FinancialBuzz.com News Commentary New York, NY (11/17/2020) – Psychedelic medicine is emerging as a breakthrough for mental health. After decades of research, drugs like psilocybin and ketamine are finally ready to move from the lab into the pharmacy and the therapist...

Dr. Rakesh Jetly Appointed Chief Medical Officer Company Announces International Expansion of Clinical Trial Sites for Phase 2A Study into Psychedelic Treatments for PTSD in Veterans VANCOUVER, British Columbia, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Mydecine Innova...

Mydecine Innovations Group Retains KCSA Strategic Communications KCSA to provide Public Relations and Social Media Counsel PR Newswire NEW YORK, Nov. 6, 2020 NEW YORK , Nov. 6, 2020 /PRNewswire/ -- Mydecine Innovations Group (CSE: MYCO) (OTC: MYCO...

Voters in New Jersey, Arizona, Montana and South Dakota have voted to legalize recreational marijuana, meaning 1 in 3 Americans now live in a state where adult pot use is legal.South Dakota and Mississippi voters also approved measures to legalize medical marijuana.Despite the news, a big pul...

Besides casting their votes for the presidential election, voters in Oregon this week will decide on decriminalizing hard drugs via a ballot initiative called Measure 110.The bill would decriminalize personal possession of less than one gram of heroin or methamphetamine; two grams of cocaine;...

VANCOUVER, British Columbia, Oct. 16, 2020 (GLOBE NEWSWIRE) -- MYDECINE INNOVATIONS GROUP, INC., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”) is pleased to announce the appointment of UK-based Boustead Capital Markets LLP (“Boustead&#...

VANCOUVER, British Columbia, Oct. 14, 2020 (GLOBE NEWSWIRE) -- NeuroPharm, Inc. (“NeuroPharm”), a wholly-owned subsidiary of Mydecine Innovations Group, Inc., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) announced today it has engaged FreeMind Group LLC to assist NeuroPharm in securin...

Mydecine Innovations (MYCOF) wholly-owned subsidiary, NeuroPharm has filed a provisional patent application with the USPTO covering composition of matter claims regarding a psychedelic therapy enhancer for the treatment of certain psychiatric disorders, including PTSD.The patent applicat...

VANCOUVER, British Columbia, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce its wholly-owned subsidiary, NeuroPharm Inc. ("NeuroPharm”), has filed a provisional patent applicat...